Ispecimen Inc. - ISPC STOCK NEWS

iSpecimen Inc. (ISPC) reported strong Q2 2024 results, with revenue increasing 76% year-over-year to $2.86 million. The company's operational improvements, including the Next Day Quotes program and Supplier Refresh initiative, contributed to this growth. Key highlights include:

- 58% conversion rate of Next Day Quotes to purchase orders in H1 2024
- Over 105 unique supplier organizations under contract as of June 30, 2024
- Cash and available-for-sale securities of $2.15 million as of June 30, 2024

The company's net loss decreased to $2.11 million, or $(0.19) per share, compared to a net loss of $3.50 million, or $(0.39) per share, in Q2 2023. iSpecimen also appointed Brielan Smiechowski as SVP of Sales and Business Development to focus on key customer accounts and implement a more robust outbound sales structure.

iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace connecting scientists with biospecimen providers for medical research, has announced its plans to report second quarter 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call and audio webcast at 8:30 a.m. Eastern Time, featuring remarks by CEO Tracy Curley.

Interested parties can join the live call at +1-800-717-1738 (U.S. Toll Free) or +1-646-307-1865 (International). A webcast will be available, and a replay of the call will be accessible until August 20, 2024. The earnings report and subsequent call may provide insights into iSpecimen's financial performance and future outlook.

iSpecimen Inc. (Nasdaq: ISPC) reported Q1 2024 financial results, highlighting a focus on Next Day Quotes program to expedite biospecimen transactions, resulting in improved market position and growth prospects. By strategically refining the supplier network, 40% of all quotes were Next Day Quotes in Q1 2024, with a high conversion rate to purchase orders. The Company aims to transition a majority of its business to Next Day Quotes for enhanced financial performance. Despite a reduction in revenue due to a decrease in specimen count, the average selling price per specimen increased, offsetting the impact. iSpecimen also announced a strategic partnership with TriMetis Life Sciences to enhance tissue-based research.

iSpecimen, a global online marketplace connecting scientists with healthcare specimen providers, will report its Q1 2024 financial results on May 7, 2024, with a conference call featuring CEO Tracy Curley.

iSpecimen Inc. (ISPC) reported financial and operating results for 2023, focusing on profitability, revenue growth, and operational efficiencies. The company achieved its strongest sales month in December 2023, with revenue of $1.7 million. Despite a decrease in specimen count, the average selling price per specimen increased by 7%. iSpecimen also saw a 39% increase in the conversion of quotes to purchase orders in Q4 2023. The company had over 230 unique supplier organizations and 600 unique customer organizations by the end of 2023. Financially, revenue for 2023 was $9.93 million, with a net loss of $11.10 million. Cash and cash equivalents were $5.01 million as of December 31, 2023. iSpecimen entered into an At the Market Offering Agreement to issue and sell shares of common stock up to $1.5 million for further capital investments or general corporate purposes.

iSpecimen Inc. (ISPC) reschedules its financial results announcement to March 13, 2024, after the market closes, and conference call to March 14, 2024, featuring CEO Tracy Curley.

iSpecimen Inc. (ISPC) will report its financial results for the full year ended December 31, 2023, before the market opens on March 13, 2024. A conference call and webcast featuring remarks by CEO Tracy Curley will follow at 8:30 a.m. Eastern Time.

iSpecimen Inc. partners with TriMetis Life Sciences to enhance quality control and assurance through digital AI histopathology services. The partnership aims to revolutionize tissue assessment for preclinical research by utilizing AI-powered solutions to standardize and enhance tissue sample evaluation, focusing on solid tumor types. This initiative will integrate technology solutions from TriMetis into iSpecimen's platform, providing researchers and suppliers access to critical data and AI-enhanced information. The partnership seeks to streamline procurement processes, increase accuracy, and reduce delays, ultimately cutting costs and delivering better outcomes for patients worldwide.

iSpecimen Inc. (ISPC) will participate in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024. Tracy Curley, CEO, will present at 10:00 a.m. ET. The company connects scientists with healthcare specimen providers for medical research.